Document is current

Article History

Received: 7 November 2023

Accepted: 7 March 2025

First Online: 17 March 2025

Declarations

:

: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. The study protocol was reviewed and granted an exemption by the Northwestern University Institutional Review Board, STU#00215981.

: Verbal informed consent was obtained from participants to participate in the study, written informed consent was not required as the study protocol was deemed exempt by the Northwestern University Institutional Review Board.

: Author BMS is a Consultant for UroGPO, Clovis Oncology, Janssen Oncology and Honorarium from AUA and Invitae. Scientific Advisory Board member for the TARGET study. Author DD is a Consultant for the Centers for Disease Control and Prevention, Division of Cancer Prevention and Control, and the Genetic Testing Advisory Board for AIM/Carelon; Honorarium for Facing Our Risk of Cancer Empowered (FORCE) for the XRAYS study, and Natera’s Hereditary Cancer Advisory Board. Author AER is a Consultant for Astellas, Bayer, Blue Earth, Janssen Oncology, Pfizer, Myovant, Veracyte, Lantheus and Honorarium form the American Urological Association and National Comprehensive Cancer Network. Authors BP, SEG, and ABM have no conflicts of interest to report.